Monica Morrow joins Memorial Sloan-Kettering Cancer Center

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

NEW YORK-Monica Morrow, MD, has joined the staff of Memorial Sloan-Kettering Cancer Center as chief of the Breast Service in the Department of Surgery. Dr. Morrow is also the incumbent of the Anne Burnett Windfohr Chair of Clinical Oncology, effective January 2009.

“We are very fortunate that Dr. Morrow, one of the country’s preeminent breast cancer surgeons, has joined our staff,” said Peter Scardino, MD, chair of the Department of Surgery. “Dr. Morrow is a superb physician, a distinguished spokesperson for breast cancer, and brings years of experience in surgical oncology to her new role.”

For more than 20 years, Dr. Morrow has been a leader in the treatment and prevention of breast cancer. After completing her surgical oncology training at MSKCC, she led the University of Chicago Hospital and Northwestern Memorial Hospital’s clinical breast programs. She served as co-principal investigator of Northwestern University’s Specialized Program of Research Excellence in Breast Cancer and, in 1996, received one of three inaugural grants from the Department of Defense Center for Excellence to increase access to modern multidisciplinary breast cancer care.

Prior to her appointment at MSKCC, she was chairman of surgical oncology at Fox Chase Cancer Center where she held the G. Willing “Wing” Pepper Chair in Cancer Research.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.